(SRTA) Strata Critical Medical, Inc. Company Overview

What does Strata Critical Medical do?

Strata Critical Medical, Inc. is a Nasdaq-listed healthcare logistics and clinical-services company trading under SRTA. It coordinates donor-organ recovery, assessment, preservation, transport, and placement, and supplies perfusion staffing and equipment to cardiovascular surgery programs. Its integrated model serves transplant hospitals, organ procurement organizations, and other healthcare providers.

The one-call transplant platform

The Logistics segment, marketed under Trinity Medical Solutions, moves organs, teams, blood, and tissue by dedicated aircraft, commercial courier, and ground transport, while TOPS provides organ-placement administration. The Clinical segment, marketed primarily under Keystone Perfusion, performs surgical recovery, normothermic regional perfusion, preservation, cardiac perfusion, blood management, ECMO support, temporary staffing, and equipment rental. The 2025 Form 10-K reported 601 employees: 223 in Logistics, 359 in Clinical, and 19 at corporate.

How does Strata make money?

Strata earns revenue directly from transplant centers, OPOs, hospitals, and other healthcare organizations. Air and ground transport are generally billed per completed trip. Organ-placement contracts usually carry fixed monthly fees based on program size. Clinical arrangements commonly combine retainers, per-case charges, staffing commitments, equipment rentals, and disposables.

How cash moves through the model

Network density is the core margin driver. Growth requires matching scarce clinicians, aircraft, and ground capacity to unpredictable demand. Selected aircraft ownership can improve uptime and economics in busy corridors, but adds depreciation, maintenance, and capital requirements.

Which segments and services matter most?

Logistics remains the base

Logistics produced $47.6 million of Q1 2026 revenue and $9.2 million of gross profit. Revenue grew 32.4% year over year, while shorter routes and winter airport closures restrained results. Gross margin was 19.3%, down 30 basis points year over year and 220 basis points sequentially.

Clinical is the higher-margin adjacency

Clinical contributed $19.8 million of Q1 2026 revenue and $5.0 million of gross profit. Its 25.0% gross margin exceeded Logistics by 570 basis points. Sequential revenue rose 12.7% and gross profit 29.2%, led by 26.7% growth in Transplant Clinical.

What does Strata’s latest quarter show?

The latest official reporting package is the quarter ended March 31, 2026. The Q1 2026 earnings release and accompanying Form 10-Q show a transformed company: year-over-year comparisons include only the legacy Logistics business in the prior period, while sequential comparisons better capture the post-Keystone structure.

Why GAAP profit needs interpretation

Q1 operating income remained negative, while continuing-operations net income became positive because non-operating income added $5.4 million. Researchers should track gross profit for unit economics, operating income for fully loaded profitability, and operating cash flow for conversion rather than treating one adjusted metric as sufficient.

How did Blade become Strata?

Strata is the product of a rapid portfolio pivot. The public entity originated through a 2021 merger involving Experience Investment Corp. and Blade, added Trinity later that year, expanded medical logistics, and made healthcare central by divesting Passenger in 2025.

Turning points that still shape the thesis

1. May 2021
   The Experience Investment Corp. merger made Blade public and created the listed capital base for the later medical pivot.
2. September 2021
   Trinity added multimodal organ transport and transplant-center relationships.
3. 2024
   Ten fixed-wing aircraft and the $2.2M CJK asset purchase increased control in selected corridors and New York ground logistics.
4. August 2025
   Passenger was sold to Joby; the company adopted the Strata name and SRTA ticker.
5. September 2025
   The $124M Keystone acquisition added recovery, NRP, cardiac perfusion, and hospital services.
6. November 2025
   Investor Day formalized the roll-up plan, a roughly 13% 2029 adjusted EBITDA margin objective, and prospective capital deployment.
7. April–June 2026
   Ohio Valley, Louisville, and HLT-NRP expanded perfusion and transplant-surgeon coverage.

FY2025 is therefore a transition period: Passenger appears in discontinued operations, Keystone entered only on September 16, and newer bolt-ons closed after Q1 2026. A valuation model should separate organic growth, portfolio change, and acquisition timing rather than extrapolate the 87.4% Q1 headline growth rate.

What gives Strata a competitive advantage?

Strata’s potential moat is coordinated density. A transplant event may require a recovery surgeon, perfusionist, preservationist, aircraft, ground transport, placement support, and continuous communication. Supplying several pieces through one network can reduce handoffs and travel. Approximately 20 air bases, 13 recovery hubs, a national clinical workforce, and customer relationships create the possibility of faster response and higher utilization.

Why density and trust matter

Barriers extend beyond capital. Credentials, aviation compliance, chain-of-custody controls, dispatch reliability, and trust accumulate over time. Technology supports staffing, training, organ evaluation, procurement, and logistics. Cross-selling matters because one recovery can create preservation and transport demand, while regional perfusion staff may support nearby transplant cases.

Where competitors can attack

Competition is fragmented. The 10-K identifies Part 135 operators, logistics coordinators, internal hospital and OPO teams, organ-evaluation specialists, clinical-service firms, and device manufacturers that bundle support. Fragmentation creates consolidation room, but customers can still insource functions or source each workflow separately.

Clinical roll-up strategy is changing the capital profile

Management’s strategy extends beyond organic transplant growth. The 2025 Investor Day framed perfusion and related clinical services as a fragmented market suited to bolt-on acquisitions. The logic is both financial and operational: acquired clinicians and hospital contracts add recurring revenue, while the same workforce may support preservation or recovery cases and improve regional density.

Three post-quarter deals demonstrate the playbook

The Ohio Valley, Louisville, and HLT-NRP announcements imply $38.5 million of stated purchase value or upfront consideration after Q1, excluding Louisville’s potential $4.0 million earn-out. HLT-NRP used approximately 80% cash and 20% stock.

The integration trade-off

Acquisitions can accelerate geographic coverage, cross-selling, and recruiting, but also add amortization, contingent consideration, stock issuance, and integration costs. Keystone cost $124 million, funded about 88% with cash and 12% with stock. Its cited purchase multiple and cash-conversion expectations were forward-looking non-GAAP estimates, so realized retention, gross profit, and overhead leverage matter more than the announcement economics.

How financially strong is Strata?

Annual context shows both scale and transition noise

Liquidity is meaningful, but capital intensity is rising

At March 31, 2026, Strata had $58.7 million of cash, $0.1 million of short-term investments, $327.6 million of assets, $41.9 million of liabilities, and $285.7 million of equity. Goodwill and net intangibles totaled $134.9 million, making acquisition performance relevant to impairment risk. Property and equipment reached $40.1 million.

A $30 million JPMorgan asset-backed revolver, expandable to $50 million subject to conditions, was undrawn at March 31. The latest acquisitions closed afterward, so future analysis must reconcile cash, debt, stock issuance, contingent consideration, and aircraft purchases before treating Q1 liquidity as fully available.

Which KPIs best explain Strata’s performance?

Revenue alone is inadequate because route length, segment mix, aircraft ownership, transplant activity, and acquisitions all move the economics. The useful dashboard links network density to segment margins, central-cost leverage, and cash conversion.

A practical monitoring dashboard

Who owns Strata stock, and how is it governed?

Strata has one vote per common share rather than a founder-controlled dual-class structure. However, beneficial ownership is concentrated enough that sponsors, executives, and specialist investors can influence governance. The 2026 proxy statement used 86.4 million shares outstanding at March 31, 2026 and disclosed directors and executive officers as a group at 15.5% beneficial ownership.

Ownership is influential but changing

The ownership periods differ and should not be treated as simultaneous current holdings. ARK’s latest Schedule 13G/A supersedes the older 7.4% proxy figure, while the Northern Right filing is newer than the proxy.

Why incentives and board structure matter

Co-CEOs Will Heyburn and Melissa Tomkiel combine finance, legal, and operating leadership. The classified board provides continuity but slows a full board change. Incentives emphasize adjusted EBITDA and free cash flow, while acquisition stock, awards, and warrants make dilution an important per-share consideration.

What opportunities, risks, and valuation drivers matter most?

Growth can come from more deceased donors, wider DCD and NRP adoption, healthcare outsourcing, new customers, deeper cross-selling, and perfusion consolidation. May 2026 guidance calls for $260–275 million of FY2026 revenue, $29–33 million of adjusted EBITDA, and $15–22 million of free cash flow before aircraft and engine acquisitions.

Risk map tied to financial statements

What matters in a DCF

A DCF should separate organic Logistics growth, Clinical growth, and acquired revenue by closing date. Model segment margins independently, then central costs and fully loaded GAAP expenses. Reinvestment must include maintenance, software, aircraft purchases, and acquisition spending rather than only management’s free-cash-flow-before-aircraft measure.

Terminal assumptions require caution because regulation, clinical liability, labor scarcity, and aviation dependence increase risk. Goodwill, stock consideration, warrants, and compensation also affect per-share value. The decisive bridge is whether network density produces durable margin expansion and free cash flow after required reinvestment.

What is the key takeaway from Strata analysis?

Strata is attempting to coordinate fragmented transplant and cardiovascular workflows in one national network. Logistics supplies customer relationships and transport; Clinical adds higher-margin recovery, NRP, preservation, and perfusion; acquisitions add density and hospital contracts. Q1 2026 showed scale with $67.4 million of revenue, 21.0% gross margin, $6.4 million of adjusted EBITDA, and positive operating cash flow.

The model remains unproven at maturity. GAAP operations were loss-making, Logistics margin was mix-sensitive, acquisitions are accelerating, and aircraft ownership raises capital intensity. The key test is whether service breadth becomes repeatable local density, retained customers and clinicians, expanding margins, and cash after fleet and acquisition investment.